IN2014MN01575A - - Google Patents

Info

Publication number
IN2014MN01575A
IN2014MN01575A IN1575MUN2014A IN2014MN01575A IN 2014MN01575 A IN2014MN01575 A IN 2014MN01575A IN 1575MUN2014 A IN1575MUN2014 A IN 1575MUN2014A IN 2014MN01575 A IN2014MN01575 A IN 2014MN01575A
Authority
IN
India
Prior art keywords
methyl
pyrido
dimethylbutyl
pyrimidin
methylamino
Prior art date
Application number
Other languages
English (en)
Inventor
Matthew Carl Allgeier
Daniel L Flynn
Michael D Kaufman
Phenil J Patel
Craig D Wolfangel
Original Assignee
Lilly Co Eli
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47884613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN01575(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Deciphera Pharmaceuticals Llc filed Critical Lilly Co Eli
Publication of IN2014MN01575A publication Critical patent/IN2014MN01575A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
IN1575MUN2014 2012-03-07 2013-03-05 IN2014MN01575A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607702P 2012-03-07 2012-03-07
PCT/US2013/029084 WO2013134243A1 (fr) 2012-03-07 2013-03-05 Dérivés de 2-amino, 6-phenyl à substitution pyrido [2, 3 - d] pyrimidine utilisés en tant qu'inhibiteurs de la raf kinase

Publications (1)

Publication Number Publication Date
IN2014MN01575A true IN2014MN01575A (fr) 2015-05-08

Family

ID=47884613

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1575MUN2014 IN2014MN01575A (fr) 2012-03-07 2013-03-05

Country Status (39)

Country Link
US (2) US9334267B2 (fr)
EP (1) EP2850082B1 (fr)
JP (1) JP2015509536A (fr)
KR (1) KR20140129087A (fr)
CN (1) CN104302646B (fr)
AP (1) AP2014007899A0 (fr)
AR (1) AR090151A1 (fr)
AU (1) AU2013230146B2 (fr)
BR (1) BR112014018528A8 (fr)
CA (1) CA2863673A1 (fr)
CL (1) CL2014002220A1 (fr)
CO (1) CO7010837A2 (fr)
CR (1) CR20140378A (fr)
CY (1) CY1117846T1 (fr)
DK (1) DK2850082T3 (fr)
DO (1) DOP2014000200A (fr)
EA (1) EA024824B1 (fr)
EC (1) ECSP14017584A (fr)
ES (1) ES2584387T3 (fr)
HK (1) HK1202541A1 (fr)
HR (1) HRP20160654T1 (fr)
HU (1) HUE028095T2 (fr)
IL (1) IL234052A (fr)
IN (1) IN2014MN01575A (fr)
LT (1) LT2850082T (fr)
MA (1) MA37316B1 (fr)
ME (1) ME02423B (fr)
MX (1) MX2014010701A (fr)
NZ (1) NZ627454A (fr)
PE (1) PE20142338A1 (fr)
PH (1) PH12014501986B1 (fr)
PT (1) PT2850082T (fr)
RS (1) RS54840B1 (fr)
SG (1) SG11201404969YA (fr)
SI (1) SI2850082T1 (fr)
TN (1) TN2014000375A1 (fr)
TW (1) TW201348233A (fr)
UA (1) UA112340C2 (fr)
WO (2) WO2013134252A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
US20190175609A1 (en) * 2016-06-10 2019-06-13 Novartis Ag Therapeutic uses of a c-raf inhibitor
EP3558979B1 (fr) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Nouvelles quinazolines substituées benzylamino et dérivés en tant qu'inhibiteurs de sos1
AU2018258581A1 (en) * 2017-04-28 2019-11-07 Quartz Therapeutics, Inc. RAF-degrading conjugate compounds
KR20200111163A (ko) 2017-12-21 2020-09-28 베링거 인겔하임 인터내셔날 게엠베하 Sos1 억제제로서의 신규 벤질아미노 치환 피리도피리미디논 및 유도체
JP7161849B2 (ja) * 2018-01-24 2022-10-27 株式会社クラレ 第一級アミンの製造方法
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
WO2020055760A1 (fr) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Polythérapies
WO2020139828A1 (fr) 2018-12-28 2020-07-02 Deciphera Pharmaceuticals, Llc Inhibiteurs du csf1r destinés à être utilisés dans le traitement du cancer
LT3921030T (lt) 2019-02-06 2024-01-25 Eli Lilly And Company 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)karbamido dariniai, kaip kcnq stiprikliai
JP2022532034A (ja) * 2019-05-03 2022-07-13 キネート バイオファーマ インク. Rafキナーゼの阻害剤
US11530206B2 (en) 2019-05-10 2022-12-20 Deciphera Pharmaceuticals, Llc Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
WO2020231808A1 (fr) 2019-05-10 2020-11-19 Deciphera Pharmaceuticals, Llc Hétéroarylaminopyrimidine amides inhibiteurs d'autophagie et leurs procédés d'utilisation
CA3143489A1 (fr) 2019-06-17 2020-12-24 Deciphera Pharmaceuticals, Llc Inhibiteurs de l'autophagie a base d'amide d'aminopyrimidine et leurs procedes d'utilisation
AU2020329956B2 (en) 2019-08-12 2023-11-16 Deciphera Pharmaceuticals, Llc. Ripretinib for treating gastrointestinal stromal tumors
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
BR112022013109A2 (pt) 2019-12-30 2022-09-06 Deciphera Pharmaceuticals Llc Formulações de inibidor de quinase amorfo e métodos de uso das mesmas
JP2023509628A (ja) 2019-12-30 2023-03-09 デシフェラ・ファーマシューティカルズ,エルエルシー 1-(4-ブロモ-5-(1-エチル-7-(メチルアミノ)-2-オキソ-1,2-ジヒドロ-1,6-ナフチリジン-3-イル)-2-フルオロフェニル)-3-フェニル尿素の組成物
EP4157836A1 (fr) 2020-06-02 2023-04-05 Boehringer Ingelheim International GmbH 2-amino-3-cyano thiophènes annelés et leurs dérivés pour le traitement du cancer
WO2022060996A1 (fr) 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibiteurs de raf kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
JP2023550591A (ja) 2020-11-02 2023-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング EGFR阻害薬としての置換1H-ピラゾロ[4,3-c]及び誘導体
IL302807A (en) 2020-11-18 2023-07-01 Deciphera Pharmaceuticals Llc GCN2 and PERK kinase inhibitors and methods of using them
JP2024501280A (ja) 2020-12-22 2024-01-11 キル・レガー・セラピューティクス・インコーポレーテッド Sos1阻害剤およびその使用
IL307908A (en) 2021-04-23 2023-12-01 Kinnate Biopharma Inc Cancer treatment with a RAF inhibitor
US20220388986A1 (en) 2021-04-29 2022-12-08 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
TW202337431A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
WO2023099608A1 (fr) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh 2-amino-3-cyano thiophènes annelés et leurs dérivés pour le traitement du cancer
WO2023099592A1 (fr) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh 2-amino-3-cyano thiophènes annelés et leurs dérivés pour le traitement du cancer
WO2023099620A1 (fr) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Composés de dégradation de kras comprenant des 2-amino-3-cyano thiophènes annelés
TW202340209A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
WO2023099623A1 (fr) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh 2-amino-3-cyano-thiophènes annelés et dérivés pour le traitement du cancer
WO2023108103A1 (fr) 2021-12-09 2023-06-15 Deciphera Pharmaceuticals, Llc Inhibiteurs de kinase raf et leurs procédés d'utilisation
WO2023118250A1 (fr) 2021-12-23 2023-06-29 Boehringer Ingelheim International Gmbh 8-aza-quinazolines utilisés en tant qu'inhibiteurs de sos1 pénétrant dans le cerveau
WO2023173017A1 (fr) * 2022-03-09 2023-09-14 Blossomhill Therapeutics, Inc. Inhibiteurs de kras pour le traitement d'une maladie
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
US20240166629A1 (en) 2022-10-26 2024-05-23 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
US20240174641A1 (en) 2022-10-26 2024-05-30 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
US20240174642A1 (en) 2022-10-26 2024-05-30 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1447405A4 (fr) * 2001-10-17 2005-01-12 Kirin Brewery Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
EP1566379A4 (fr) * 2002-10-29 2005-11-09 Kirin Brewery DERIVES DE QUINOLINE ET DE QUINAZOLINE INHIBANT L'AUTOPHOSPHORYLATION DE Flt3 ET COMPOSITIONS MEDICALES LES CONTENANT
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8901137B2 (en) * 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf

Also Published As

Publication number Publication date
LT2850082T (lt) 2016-09-12
HK1202541A1 (en) 2015-10-02
PH12014501986A1 (en) 2014-11-24
JP2015509536A (ja) 2015-03-30
KR20140129087A (ko) 2014-11-06
IL234052A (en) 2016-05-31
TW201348233A (zh) 2013-12-01
EP2850082A1 (fr) 2015-03-25
PH12014501986B1 (en) 2014-11-24
CN104302646B (zh) 2016-05-04
US20130252977A1 (en) 2013-09-26
US20150119392A1 (en) 2015-04-30
MA37316B1 (fr) 2017-03-31
DOP2014000200A (es) 2014-10-15
RS54840B1 (sr) 2016-10-31
ES2584387T3 (es) 2016-09-27
HUE028095T2 (en) 2016-11-28
CN104302646A (zh) 2015-01-21
AU2013230146A1 (en) 2014-08-14
CO7010837A2 (es) 2014-07-31
MX2014010701A (es) 2015-03-10
AR090151A1 (es) 2014-10-22
CA2863673A1 (fr) 2013-09-12
PT2850082T (pt) 2016-07-15
AU2013230146B2 (en) 2015-09-10
EP2850082B1 (fr) 2016-05-18
ECSP14017584A (es) 2016-01-29
PE20142338A1 (es) 2015-01-10
CR20140378A (es) 2014-11-27
EA024824B1 (ru) 2016-10-31
US8741911B2 (en) 2014-06-03
UA112340C2 (uk) 2016-08-25
SG11201404969YA (en) 2014-10-30
TN2014000375A1 (en) 2015-12-21
AP2014007899A0 (en) 2014-08-31
US9334267B2 (en) 2016-05-10
EA201491456A1 (ru) 2014-12-30
SI2850082T1 (sl) 2016-07-29
WO2013134252A1 (fr) 2013-09-12
HRP20160654T1 (hr) 2016-07-01
BR112014018528A2 (fr) 2017-06-20
CL2014002220A1 (es) 2015-06-05
DK2850082T3 (en) 2016-08-15
ME02423B (fr) 2016-09-20
BR112014018528A8 (pt) 2017-07-11
CY1117846T1 (el) 2017-05-17
MA37316A1 (fr) 2016-06-30
NZ627454A (en) 2016-09-30
WO2013134243A1 (fr) 2013-09-12

Similar Documents

Publication Publication Date Title
IN2014MN01575A (fr)
IL228968A0 (en) Kinase-inhibiting pyrazolo[4,3-d]pyrimidine compounds, preparations containing them and their uses
ZA201506570B (en) 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
IL246028A0 (en) Compounds 2 - amino - 6 - fluoro - n - [ - fluoro - pyridine - 3 yl] pyrazolo (1, 5 - a ) pyrimidine - 3 - carboxamide, their solid forms, preparations containing them and methods for their preparation
EP2751112A4 (fr) Pyrazolo[3,4-d]pyrimidines substituées et utilisations de celles-ci
ZA201802181B (en) 2¿phenyl¿3,4¿dihydropyrrolo[2,1 ¿f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof
HK1221469A1 (zh) -芳基-取代的咪唑並 吡啶及其用途
SI2585467T1 (sl) Pirazolo(1,5-a)pirimidini in -triazini kot protivirusna sredstva
SI2300455T1 (sl) Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
HK1193100A1 (zh) 苯基- -氮雜-雙環 己- -基-甲酮及其作為藥物的用途
PL2634174T3 (pl) Zawierająca azot pochodna heterocykliczna mająca grupę 2-iminową i zawierający ją środek do zwalczania szkodników
EP2857403A4 (fr) Composé pyrrolo[2,1-f][1,2,4]triazine, son procédé de préparation et son application
PL2833490T3 (pl) Zelektryfikowana szyna, zwłaszcza do zasilania jednostek regałów metalowych i sposób ich wytwarzania
IL262673A (en) Pyrazolo[1,5-a]pyrimidine compound
IL235949A0 (en) Pyrrolo [2,1-f] [1,2,4] triazine derivative and uses thereof for the treatment of tumors
SG11201809760TA (en) Novel 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof
CA141929S (en) Retainer for railings
EP2976342A4 (fr) Dérivés d'imidazo[4,5-d]phénanthroline 2-substitués et leur utilisation dans le traitement du cancer
UY35034A (es) PROCESO PARA LA PREPARACIÓN DE 2-AMINO-5,8-DIMETOXI[1,2,4]TRIAZOL[1,5-c] PIRIMIDINA A PARTIR DE 4-CLORO-2,5-DIMETOXIPIRIMIDINA
IL253427A0 (en) The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose
CL2014001265A1 (es) Compuestos derivados de uracilo, inhibidores de la quinasa axl y c-met, utiles en el tratamiento del cancer.
CA142240S (en) Door stop